obesity

Obesity Drug Market Set to Hit $100 Billion by 2035, BMO Says
Obesity Drug Market Set to Hit $100 Billion by 2035, BMO Says
Yahoo/Bloomberg
Novo Nordisk
Ozempic
Wegovy
obesity
weight loss
Flag link:
Altimmune completes dosing in MOMENTUM trial to treat obesity
Altimmune completes dosing in MOMENTUM trial to treat obesity
Clinical Trials Arena
Altimmune
clinical trials
pemvidutide
obesity
Flag link:
Novo, Lilly set to dominate $71B GLP-1 drug market by 2032: J.P. Morgan
Novo, Lilly set to dominate $71B GLP-1 drug market by 2032: J.P. Morgan
Fierce Pharma
Novo Nordisk
Eli Lilly
GLP-1 agonist
obesity
Flag link:
Novo Nordisk Is Already Working on Ozempic 2.0
Novo Nordisk Is Already Working on Ozempic 2.0
Motley Fool
Novo Nordisk
diabetes
obesity
weight loss
Ozempic
Wegovy
Flag link:
Novo Nordisk launches Wegovy for obese patients in UK
Novo Nordisk launches Wegovy for obese patients in UK
Pharmaceutical Business Review
Novo Nordisk
UK
Wegovy
obesity
Flag link:
Competing in These 3 Markets Could Send Eli Lilly Stock Soaring
Competing in These 3 Markets Could Send Eli Lilly Stock Soaring
Motley Fool
Eli Lilly
Alzheimer's disease
obesity
painkillers
Flag link:
Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins
Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins
Clinical Trials Arena
Eli Lilly
retatrutide
clinical trials
NASH
obesity
diabetes
type 2 diabetes
Flag link:
Novo Bolsters Obesity Pipeline with Potential $500M Embark Biotech Buy
Novo Bolsters Obesity Pipeline with Potential $500M Embark Biotech Buy
BioSpace
Novo Nordisk
Embark Biotech
obesity
M&A
Flag link:
Boehringer preps phase 3 for dual-action obesity drug
Boehringer preps phase 3 for dual-action obesity drug
Pharmaphorum
Boehringer Ingelheim
clinical trials
obesity
survodutide
Flag link:
Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2
Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2
Fierce Pharma
Novo Nordisk
Eli Lilly
obesity
diabetes
earnings
Flag link:
Novo Nordisk bets $1.1B on Canadian biotech buyout, adding an old approach to obesity pipeline
Novo Nordisk bets $1.1B on Canadian biotech buyout, adding an old approach to obesity pipeline
Fierce Biotech
Novo Nordisk
M&A
obesity
Inversago
Flag link:
In the era of blockbuster obesity drugs, a personalized approach could boost outcomes
In the era of blockbuster obesity drugs, a personalized approach could boost outcomes
Pharma Voice
obesity
Phenomix
Novo Nordisk
Ozempic
Wegovy
Flag link:
Novo Nordisk posts 'best-case scenario' cardio outcomes data for star obesity drug Wegovy
Novo Nordisk posts 'best-case scenario' cardio outcomes data for star obesity drug Wegovy
Fierce Pharma
Novo Nordisk
Wegovy
clinical trials
cardiovascular disease
obesity
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Flag link:
Lilly's obesity drug leads to about 26% weight loss in new studies
Lilly's obesity drug leads to about 26% weight loss in new studies
Yahoo/Reuters
Eli Lilly
obesity
clinical trials
Mounjaro
Flag link:
Eli Lilly's Mounjaro shortage worsens ahead of potential obesity FDA approval
Eli Lilly's Mounjaro shortage worsens ahead of potential obesity FDA approval
Fierce Pharma
Eli Lilly
Mounjaro
obesity
weight loss
drug shortages
Flag link:
Novo Nordisk, Eli Lilly and Boehringer Ingelheim back bill to bring obesity drug coverage to Medicare
Novo Nordisk, Eli Lilly and Boehringer Ingelheim back bill to bring obesity drug coverage to Medicare
Fierce Pharma
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
obesity
Flag link:
Novartis axes secretive obesity program after high-risk, high-reward bet fails
Novartis axes secretive obesity program after high-risk, high-reward bet fails
Fierce Biotech
Novartis
obesity
pancreatic cancer
Flag link:
Hungry for more, Lilly tops off weight loss pipeline with $1.9B deal to acquire Versanis
Hungry for more, Lilly tops off weight loss pipeline with $1.9B deal to acquire Versanis
Fierce Biotech
Eli Lilly
M&A
obesity
Versanis
bimagrumab
Flag link:
Pharma finds a way to gain weight
Pharma finds a way to gain weight
EP Vantage
obesity
Eli Lilly
Novo Nordisk
Wegovy
Mounjaro
Flag link:

Pages